Skip to main navigation Skip to search Skip to main content

Targeting the Ubiquitin Proteasome System to Treat Spinal Muscular Atrophy

Project Details

Description

? DESCRIPTION (provided by applicant): Spinal muscular atrophy (SMA) is the most common inherited cause of death in infants and young children. SMA is caused by the deletion or mutation in the survival of motor neuron 1 (SMN1) gene, leading to a deficiency of the ubiquitously expressed SMN protein. Currently, there is no effective treatment option available for SMA. Evidence from studies in humans and rodents suggests that increasing SMN protein levels in the central nervous system is sufficient to ameliorate the disease phenotype and prolong survival. To identify protective modifiers of SMN protein levels we performed a genome-wide RNAi screen. Genes we identified in this screen will allow us to investigate genetic modifiers and molecular pathways that regulate SMN protein levels. These targets and pathways should provide novel avenues for therapeutic development for the treatment of SMA.
StatusFinished
Effective start/end date1/04/1631/12/20

Funding

  • National Institute of Neurological Disorders and Stroke: $303,692.00
  • National Institute of Neurological Disorders and Stroke: $303,692.00
  • National Institute of Neurological Disorders and Stroke: $303,692.00
  • National Institute of Neurological Disorders and Stroke: $303,692.00
  • National Institute of Neurological Disorders and Stroke: $303,692.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.